JAFRAL is proud to be a GMP manufacturing partner of a consortium/project for first clinical trial on combined electrochemotherapy with gene therapy with Interleukin-12 (IL-12) to improve/enhance local and systemic response to skin tumor treatment.

As of June 1 2018 JAFRAL is a part of Bio-Pharm Competence Center for Biotechnology and Pharmaceuticals.

On 20th September 2017, WHO launched report about antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including tuberculosis. Report shows a

JAFRAL is going to attend and co-sponsor at Viruses of Microbes 2018 in Wroclaw, Poland.

JAFRAL is going to attend and held presentation at Phage Therapy & Antibiotic Resistance 2018 in Florence, Italy. You are welcome to meet with our representative at the conference dr. Frenk Smrekar

Because there have not been rigorous clinical trials of phages, they can be used only on patients for whom all other options have failed.